Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Massachusetts health insurers are effectively telling the drug companies that they may seek a rapidly growing customer base ...

GLP-1 drugs bought online or at compound pharmacies could cause harm, according to Tennessee Attorney General Jonathan Skrmetti.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

In his new book, a former FDA commissioner unpacks the latest science on metabolism, weight loss, and how GLP-1 drugs ...

Data collected between 2021 and 2024 shows how long GLP-1 users continued taking the medications for weight-loss. A majority had stopped taking it by the third year.

GLP-1 drugs show promise in diabetes management, offering heart and kidney benefits, but also highlight the need for vigilance regarding new health risks.